A proposed collaboration with CBmed Ltd., Austria

Need rapid target validation?

We can help you prioritize your tumor entities for new oncology compounds

What We Deliver

CBmed integrates tissue, molecular, and clinical data into a comparative cross-tumor evidence framework for rapid indication prioritization based on:

Biospecimen Access

Access to heterogeneous, patient-
derived brain cancer samples across clinically relevant glioma subtypes.

Histopathology Analysis

Advanced 3D spheroid models that better reflect tumor biology and heterogeneity.

Molecular Profiling

State-of-the-art laboratory automation with fully integrated devices.

Fluid Biomarker Analysis

Customized assay design enabling side-by-side compound comparison under standardized, clinically meaningful conditions, supported by integrated clinical data.

Cross-Tumor Comparison

Decision-ready comparative data package to support candidate prioritization and follow-up study design.

Special Offer

To provide a low-risk entry point for collaboration, we offer an initial test phase under a special offer framework, that allows your team to evaluate target relevance in clinically meaningful patient samples in a real project setting.

This is designed to generate early prioritization insights while creating a practical foundation for broader strategic collaboration.

In this introductory phase, we will:

Access to 10 patient samples, including clinical metadata
Generate robust data using validated IHC workflows
Interpret target expression, heterogeneity, and cross-tumor patterns
Deliver first insights for indication prioritization
Define a follow-up validation study using large biobank cohorts and expand to complementary technologies

Download